Tumor-targeted immunotherapy is a remarkable breakthrough, offering the inimitable advantage of specific tumoricidal effects with reduced immune-associated cytotoxicity. However, existing platforms suffer from low efficacy, inability to induce strong immunogenic cell death (ICD), and restrained capacity of transforming immune-deserted tumors into immune-cultivated ones. Here, an innovative platform, perfluorooctyl bromide (PFOB) nanoemulsions holding MnO₂ nanoparticles (MBP), was developed to orchestrate cancer immunotherapy, serving as a theranostic nanoagent for MRI/CT dual-modality imaging and advanced ICD. By simultaneously depleting the GSH and eliciting the ICD effect via high-intensity focused ultrasound (HIFU) therapy, the MBP nanomedicine can regulate the tumor immune microenvironment by inducing maturation of dendritic cells (DCs) and facilitating the activation of CD8⁺ and CD4⁺ T cells. The synergistic GSH depletion and HIFU ablation also amplify the inhibition of tumor growth and lung metastasis. Together, these findings inaugurate a new strategy of tumor-targeted immunotherapy, realizing a novel therapeutics paradigm with great clinical significance.

肿瘤靶向免疫疗法是一个显着的突破，它提供了特定的肿瘤杀伤作用和降低免疫相关细胞毒性的独特优势。然而，现有平台存在疗效低、无法诱导强免疫原性细胞死亡（ICD）以及将免疫遗弃肿瘤转化为免疫培养肿瘤的能力受限等问题。_{在这里，开发了一种创新平台，即含有 MnO 2}纳米颗粒 (MBP)的全氟辛基溴 (PFOB) 纳米乳液，用于协调癌症免疫治疗，用作 MRI/CT 双模态成像和高级 ICD 的治疗诊断纳米剂。通过同时消耗 GSH 并通过以下方式引发 ICD 效应在高强度聚焦超声（HIFU）治疗中，MBP纳米药物可以通过诱导树突状细胞（DCs）成熟和促进CD8 ⁺和CD4 ⁺ T细胞活化来调节肿瘤免疫微环境。协同的 GSH 耗竭和 HIFU 消融也增强了对肿瘤生长和肺转移的抑制作用。总之，这些发现开创了一种新的肿瘤靶向免疫治疗策略，实现了一种具有重要临床意义的新型治疗模式。